The most common first-line therapies administered to older patients were sunitinib (52.9%), pazopanib (10.1%), and temsirolimus (9.4%). Sunitinib (61.4%), temsirolimus (7.0%), and pazopanib (6.4%) were the most commonly administered first-line therapies in the younger cohort. Although the percentage of patients receiving second-line therapy was higher among younger patients than among older patients, this difference was not significant (63.7% vs 57.2%; P =.296).
At a median follow-up of 19 months, the median OS was 31.0 months for the older patients and 33.1 months for the younger patients (P =.956).
The possibility of selection bias was identified as a potential limitation in this study, given that only patients who had received first-line therapy were included.
“Our findings suggest that older patients warrant proportionate representation on clinical trials. Furthermore, these findings can help clinicians in selecting initial treatment and planning treatment sequencing,” the study authors concluded.
Reference Hahn AW, Esther J, Haaland B, et al. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients [published online August 8, 2019]. J Geriatr Oncol. doi: 10.1016/j.jgo.2019.07.002